Nasus Pharma (NSRX) Cash from Financing Activities (2024)
Nasus Pharma (NSRX) reported Cash from Financing Activities of $881000.0 for Q4 2024.
Nasus Pharma (NSRX) Cash from Financing Activities (2024) Analysis & Trends
Nasus Pharma has reported Cash from Financing Activities for 1 years, with the latest figure at $881000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 366.70 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 881,000.00 |
| Dec 31, 2024 | 881,000.00 |